OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0000946486

WINDTREE THERAPEUTICS INC /DE/ (WINT)

WINDTREE THERAPEUTICS INC /DE/ (CIK 0000946486, ticker WINT, EIN 94-3171943) reported revenue of $198,000 for FY2019 (2019-01-01 to 2019-12-31) and net income of -$1.79 million (-$1,787,000) for FY2024 (2024-01-01 to 2024-12-31), as filed in its 10-K filed 2020-04-03 (accession 0001437749-20-006970) and its 10-K filed 2025-04-15 (accession 0001437749-25-012093).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0000946486
TickersWINT (OTC)
EIN94-3171943
SIC industry code2836 Biological Products, (No Diagnostic Substances)
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_2c8ceq90vemprwga8t665jangy
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$198,000FY20192019-01-01 to 2019-12-3110-K2020-04-030001437749-20-006970Revenues
Net income-$1,787,000FY20242024-01-01 to 2024-12-3110-K2025-04-150001437749-25-012093NetIncomeLoss
Total assets$27,875,000FY2024as of 2024-12-3110-K2025-04-150001437749-25-012093Assets
Total liabilities$14,698,000FY2024as of 2024-12-3110-K2025-04-150001437749-25-012093Liabilities
Stockholders' equity$9,996,000FY2024as of 2024-12-3110-K2025-04-150001437749-25-012093StockholdersEquity
Operating cash flow-$15,402,000FY20242024-01-01 to 2024-12-3110-K2025-04-150001437749-25-012093NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$2.73 per shareFY20212021-01-01 to 2021-12-3110-K2022-03-310001437749-22-007757EarningsPerShareBasicAndDiluted
Shares outstanding3,555,953 sharesFY2024as of 2025-04-1510-K2025-04-150001437749-25-012093EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2015-2024, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20192019-01-01 to 2019-12-31$198,00010-K2020-04-030001437749-20-006970
RevenueFY20182018-01-01 to 2018-12-31$1,788,00010-K2020-04-030001437749-20-006970
RevenueFY20172017-01-01 to 2017-12-31$1,485,00010-K/A2019-04-230001437749-19-007802
RevenueFY20162016-01-01 to 2016-12-31$2,042,00010-K2018-04-170001437749-18-007033
RevenueFY20152015-01-01 to 2015-12-31$987,00010-K2017-03-310001437749-17-005788
Net incomeFY20242024-01-01 to 2024-12-31-$1,787,00010-K2025-04-150001437749-25-012093
Net incomeFY20232023-01-01 to 2023-12-31-$20,291,00010-K2025-04-150001437749-25-012093
Net incomeFY20222022-01-01 to 2022-12-31-$39,208,00010-K2024-04-160001437749-24-012210
Net incomeFY20212021-01-01 to 2021-12-31-$67,636,00010-K2023-03-310001437749-23-008864
Net incomeFY20202020-01-01 to 2020-12-31-$32,566,00010-K2022-03-310001437749-22-007757
Net incomeFY20192019-01-01 to 2019-12-31-$27,475,00010-K2021-03-290001437749-21-007493
Net incomeFY20182018-01-01 to 2018-12-31-$20,533,00010-K2020-04-030001437749-20-006970
Net incomeFY20172017-01-01 to 2017-12-31-$18,446,00010-K/A2019-04-230001437749-19-007802
Net incomeFY20162016-01-01 to 2016-12-31-$39,490,00010-K2018-04-170001437749-18-007033
Net incomeFY20152015-01-01 to 2015-12-31-$55,170,00010-K2017-03-310001437749-17-005788

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2025-11-192025-09-300001437749-25-035751wint20250930_10q.htm
10-Q2025-08-192025-06-300001437749-25-027382wint20250630_10q.htm
10-Q2025-05-152025-03-310001437749-25-017261wint20250331_10q.htm
10-K2025-04-152024-12-310001437749-25-012093wint20241231_10k.htm
10-Q2024-11-262024-09-300001437749-24-036277wint20240930c_10q.htm
10-Q2024-08-192024-06-300001437749-24-027232wint20240630_10q.htm
10-Q2024-05-152024-03-310001437749-24-017124wint20240331_10q.htm
10-K2024-04-162023-12-310001437749-24-012210wint20231231_10k.htm
10-Q2023-11-092023-09-300001437749-23-031246wint20230930_10q.htm
10-Q2023-08-072023-06-300001437749-23-022308wint20230630_10q.htm
10-Q2023-05-152023-03-310001437749-23-014594wint20230331_10q.htm
10-K/A2023-05-012022-12-310001437749-23-011914wint20221231_10ka.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0000946486published by the sourcedata.sec.gov/submissions/CIK0000946486.json2026-10-21
Employer Identification Number (EIN) · US-EIN94-3171943published by the sourcedata.sec.gov/submissions/CIK0000946486.json2026-10-21

Former names

NameFromTo
DISCOVERY LABORATORIES INC /DE/1997-12-052016-04-18
ANSAN PHARMACEUTICALS INC1997-08-261997-07-21
ANSAN INC1996-09-051996-05-15

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0000946486.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0000946486.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000946486" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000946486/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0000946486/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"946486"}

On SEC EDGAR

About this data